Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

Similar articles for PubMed (Select 23709115)

1.

Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans.

Evans EK, Tester R, Aslanian S, Karp R, Sheets M, Labenski MT, Witowski SR, Lounsbury H, Chaturvedi P, Mazdiyasni H, Zhu Z, Nacht M, Freed MI, Petter RC, Dubrovskiy A, Singh J, Westlin WF.

J Pharmacol Exp Ther. 2013 Aug;346(2):219-28. doi: 10.1124/jpet.113.203489. Epub 2013 May 24.

2.

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ.

Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80. doi: 10.1073/pnas.1004594107. Epub 2010 Jul 6.

3.

RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.

Xu D, Kim Y, Postelnek J, Vu MD, Hu DQ, Liao C, Bradshaw M, Hsu J, Zhang J, Pashine A, Srinivasan D, Woods J, Levin A, O'Mahony A, Owens TD, Lou Y, Hill RJ, Narula S, DeMartino J, Fine JS.

J Pharmacol Exp Ther. 2012 Apr;341(1):90-103. doi: 10.1124/jpet.111.187740. Epub 2012 Jan 6.

4.

Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.

Whang JA, Chang BY.

Drug Discov Today. 2014 Aug;19(8):1200-4. doi: 10.1016/j.drudis.2014.03.028. Epub 2014 Apr 12. Review.

PMID:
24721226
5.

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, Carano RA, Darrow J, Davies DR, DeForge LE, Diehl L, Ferrando R, Gallion SL, Giannetti AM, Gribling P, Hurez V, Hymowitz SG, Jones R, Kropf JE, Lee WP, Maciejewski PM, Mitchell SA, Rong H, Staker BL, Whitney JA, Yeh S, Young WB, Yu C, Zhang J, Reif K, Currie KS.

Nat Chem Biol. 2011 Jan;7(1):41-50. doi: 10.1038/nchembio.481. Epub 2010 Nov 28.

PMID:
21113169
6.

Ibrutinib and novel BTK inhibitors in clinical development.

Akinleye A, Chen Y, Mukhi N, Song Y, Liu D.

J Hematol Oncol. 2013 Aug 19;6:59. doi: 10.1186/1756-8722-6-59. Review.

7.
8.

Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.

Coffey G, DeGuzman F, Inagaki M, Pak Y, Delaney SM, Ives D, Betz A, Jia ZJ, Pandey A, Baker D, Hollenbach SJ, Phillips DR, Sinha U.

J Pharmacol Exp Ther. 2012 Feb;340(2):350-9. doi: 10.1124/jpet.111.188441. Epub 2011 Oct 31.

9.

Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: a potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints.

Hsu J, Gu Y, Tan SL, Narula S, DeMartino JA, Liao C.

Immunol Lett. 2013 Feb;150(1-2):97-104. doi: 10.1016/j.imlet.2012.12.007. Epub 2012 Dec 21.

PMID:
23266841
11.

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.

Chang BY, Huang MM, Francesco M, Chen J, Sokolove J, Magadala P, Robinson WH, Buggy JJ.

Arthritis Res Ther. 2011 Jul 13;13(4):R115. doi: 10.1186/ar3400.

12.

Complementary roles for CD19 and Bruton's tyrosine kinase in B lymphocyte signal transduction.

Fujimoto M, Poe JC, Satterthwaite AB, Wahl MI, Witte ON, Tedder TF.

J Immunol. 2002 Jun 1;168(11):5465-76.

14.
15.

A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.

Eda H, Santo L, Cirstea DD, Yee AJ, Scullen TA, Nemani N, Mishima Y, Waterman PR, Arastu-Kapur S, Evans E, Singh J, Kirk CJ, Westlin WF, Raje NS.

Leukemia. 2014 Sep;28(9):1892-901. doi: 10.1038/leu.2014.69. Epub 2014 Feb 12.

PMID:
24518207
16.

PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.

Winer ES, Ingham RR, Castillo JJ.

Expert Opin Investig Drugs. 2012 Mar;21(3):355-61. doi: 10.1517/13543784.2012.656199. Epub 2012 Feb 3. Review.

PMID:
22300471
17.

Bruton's tyrosine kinase mediates NF-kappa B activation and B cell survival by B cell-activating factor receptor of the TNF-R family.

Shinners NP, Carlesso G, Castro I, Hoek KL, Corn RA, Woodland RT, Scott ML, Wang D, Khan WN.

J Immunol. 2007 Sep 15;179(6):3872-80. Erratum in: J Immunol. 2007 Nov 1;179(9):6369. Woodland, Robert L [corrected to Woodland, Robert T].

18.

More than just B-cell inhibition.

Ruderman EM, Pope RM.

Arthritis Res Ther. 2011 Aug 30;13(4):125. doi: 10.1186/ar3439.

19.

Selective inhibition of BTK prevents murine lupus and antibody-mediated glomerulonephritis.

Rankin AL, Seth N, Keegan S, Andreyeva T, Cook TA, Edmonds J, Mathialagan N, Benson MJ, Syed J, Zhan Y, Benoit SE, Miyashiro JS, Wood N, Mohan S, Peeva E, Ramaiah SK, Messing D, Homer BL, Dunussi-Joannopoulos K, Nickerson-Nutter CL, Schnute ME, Douhan J 3rd.

J Immunol. 2013 Nov 1;191(9):4540-50. doi: 10.4049/jimmunol.1301553. Epub 2013 Sep 25.

20.

Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.

MacPartlin M, Smith AM, Druker BJ, Honigberg LA, Deininger MW.

Leukemia. 2008 Jul;22(7):1354-60. doi: 10.1038/leu.2008.126. Epub 2008 Jun 12.

PMID:
18548107
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk